Endocrine Abstracts

The recent discovery that genetically-modified α-cells can regenerate and convert into β-like cells in vivo holds great promise for diabetes research. However, to eventually translate these findings to human, it is crucial to discover compounds with similar activities. Herein, we report the identification of GABA as an inducer of α-to-β-like cell conversion in vivo. This conversion induces α-cell replacement mechanisms through the mobilization of duct-lining precursor cells that adopt an α-cell identity prior to being converted into β-like cells, solely upon sustained GABA exposure. Importantly, these neo-generated β-like cells are functional and can repeatedly reverse chemically-induced diabetes in vivo. Similarly, the treatment of transplanted human islets with GABA results in a loss of α-cells and a concomitant increase in β-like cell counts, suggestive of α-to-β-like cell conversion processes also in humans. This newly discovered GABA-induced α-cell-mediated β-like cell neogenesis could therefore represent an unprecedented hope towards improved therapies for diabetes.